Bench to Bedside (B2B) webinar series
Series cost: Free for members
(includes on-demand access for all three webinars)
In advance of the 2021 ARVO Bench to Bedside (B2B) Meeting, ARVO is hosting an educational webinar series that tackles the following need-to-know topics:
It is important for bench scientists who innovate to learn how and when to communicate with stakeholders who can potentially help fund discoveries into marketable products, drugs, and remedies that treat diseases that cause blindness. Following a period of strong financial results and investments in the ophthalmology space in 2019, most virtual startups have needed to pivot to prioritize other interests.
Featuring a panel of seasoned serial entrepreneurs, this webinar will help innovators and particularly those in virtual companies to ask questions and learn basic strategies and tactics to determine next steps in raising funds to sustain development. These will include the use of pitch decks and the identification of multiple funding platforms including nondiluted government grants, private equity, and co-licensing.
Intellectual property is intrinsically related to the successful venture of new businesses. The protection of intellectual property through patents is often misunderstood, undervalued and overlooked by bench scientists and innovators. Many times, the scientist/innovator transfers the know-how surrounding a particular invention to a larger institution, but isn’t clear how this act benefits them in the long run.
Featuring a panel of scientists and experts in patent law and tech transfer, this webinar will permit scientists, and particularly those in the business of preventing blindness, to develop win-win strategies for technology transfer and patent protection.
It is important for bench scientists who innovate to learn how and when to communicate with stakeholders who can potentially help translate laboratory discoveries into marketable products, drugs, and remedies that treat visual disorders.
This webinar will help innovators and new companies determine how to establish an early and productive dialogue with the FDA to gain valuable insights that could boost their chances of success and produce cost-effective clinical development strategies in drugs, devices, biologics and generics.